FierceBiotech

FDA Approves Lucentis® (Ranibizumab Injection) for the Treatment of Macular Edema Following Retinal Vein Occlusion

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved ...
Medscape

Limit Ranibizumab Injections in Macular Degeneration

LONDON — The lucky number is 7 — or 7.1 to be exact — the mean optimum number of injections of intravitreal ranibizumab (Lucentis, Genentech) that should be given during the first year of treatment ...
Nasdaq

Phase III Data Show Port Delivery System With Ranibizumab Enabled Over 98% of Patients to Go Six Months Between Treatments for Neovascular Age-Related Macular Degeneration

In the Archway study, Port Delivery System with ranibizumab (PDS) demonstrated non-inferior and equivalent visual acuity outcomes compared with monthly ranibizumab eye injections, and a favorable ...
Healio

Minimal differences seen in yearly number of injections and cost for ranibizumab, aflibercept

Please provide your email address to receive an email when new articles are posted on . ORLANDO, Fla. — Differences between ranibizumab and aflibercept for treatment of neovascular age-related macular ...
Ophthalmology Times

New tried-and-true treatments for retinal vein occlusion

More recently established treatments for RVO have taken a giant leap forward from laser photocoagulation since intravitreally ...
Science Daily

Diabetic macular edema: Ranibizumab injections plus laser therapy results in dramatic visual improvement

Researchers have shown that ranibizumab (Lucentis) eye injections, often in combination with laser treatment, result in better vision than laser treatment alone for diabetes-associated swelling of the ...
Business Wire

Port Delivery System With Ranibizumab Shows Positive Phase III Results in Neovascular Age-Related Macular Degeneration

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from the Phase III Archway study, evaluating ...
FierceBiotech

FDA Approves Lucentis® (Ranibizumab Injection) for Treatment of Diabetic Macular Edema (DME)

<0> GenentechMedia Contact:Terence Hurley, 650-467-6800orInvestor Relations:Thomas Kudsk Larsen, 650-467-2016Karl Mahler, 011 41 61 687 8503 </0> Genentech, a member of the Roche Group (SIX: RO, ROG; ...
Healio

More inflammation observed after aflibercept vs. ranibizumab injection

Please provide your email address to receive an email when new articles are posted on . VANCOUVER, British Columbia — While eye pain outcomes were similar within a week of injection of either ...
Business Wire

FDA Accepts Application for Genentech’s Port Delivery System With Ranibizumab (PDS) for Treatment of Wet Age-Related Macular Degeneration (AMD)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the ...
Nature

Treatment patterns of ranibizumab intravitreal injection and dexamethasone intravitreal implant for retinal vein occlusion in the USA

Ranibizumab, an anti-vascular endothelial growth factor, and dexamethasone, a corticosteroid, have been shown to be effective in treating macular oedema secondary to retinal vein occlusion (RVO) ...